This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Factors Likely to Shape Colgate's (CL) Q1 Earnings Outcome
by Zacks Equity Research
Colgate's (CL) growth efforts make us confident that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.
Can Boston Beer (SAM) Beat Q1 Earnings Estimates Despite Odds?
by Zacks Equity Research
Boston Beer's (SAM) first-quarter results are likely to reap benefits of the ongoing strength in shipments and depletions. However, soft Samuel Adams brand performance and higher costs remain woes.
Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ
by Sanghamitra Saha
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
Altria (MO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Pricing & RRPs Aid Altria's (MO) Q1 Earnings Growth?
by Zacks Equity Research
Altria's (MO) Q1 performance is likely to gain from RRPs and high pricing. However, receding cigarette sales are a concern.
Can Coca-Cola (KO) Retain Earnings Trend in Q1 Despite Odds?
by Zacks Equity Research
Coca-Cola (KO) is likely to continue gaining from product launches, and focus on lifting and shifting successful brands globally in first-quarter 2019. However, currency headwinds may hurt results.
5 Consumer Staples Stocks Set to Beat This Earnings Season
by Zacks Equity Research
Although high input costs are a concern for players in the consumer staples sector, a few are likely to gain from prudent acquisitions, savings and brand augmenting efforts.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $56.43 in the latest trading session, marking a -0.9% move from the prior day.
Marijuana ETF Down 9% in Past Month: Time to Enter the Space?
by Sanghamitra Saha
Growing global acceptance, increasing legalization and beaten-down prices open up room for marijuana ETF investing.
Key Factors Shaping Procter & Gamble's (PG) Q3 Earnings
by Zacks Equity Research
Procter & Gamble's (PG) product innovation, packaging and marketing initiatives, and productivity and cost-saving plan are likely to aid growth. Higher commodity and shipping costs are concerns.
IMBBY vs. MO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IMBBY vs. MO: Which Stock Is the Better Value Option?
Will RRPs & Pricing Drive Philip Morris' (PM) Q1 Earnings?
by Zacks Equity Research
Philip Morris' (PM) Q1 performance to gain from high pricing and advancements in RRPs. However, declining cigarette volumes are a worry.
The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors
Can Altria (MO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Altria (MO) and Becton, Dickinson (BDX).
Altria (MO) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $55.12, moving -0.29% from the previous trading session.
Altria to Boost Interests in JUUL, Aims to Gain Voting Rights
by Zacks Equity Research
Altria (MO) provides information related to investment in JUUL to the FTC. It seeks to gain voting interests in JUUL.
Philip Morris' (PM) Year of Unsmoke Underscores Focus on RRPs
by Zacks Equity Research
Philip Morris (PM) is benefiting from focus on reduced-risk products, which is reconfirmed by its latest launch of "The Year of Unsmoke."
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $57.74, marking a +0.54% move from the previous day.
IMBBY vs. MO: Which Stock Is the Better Value Option?
by Zacks Equity Research
IMBBY vs. MO: Which Stock Is the Better Value Option?
Philip Morris Looks Alluring on Gains from RRPs & Pricing
by Zacks Equity Research
Philip Morris (PM) is progressing well with bolstering presence in the low-risk tobacco space. Further, the company's pricing strategies are yielding results.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $56.56, moving +1.14% from the previous trading session.
Altria (MO) Hurt by Low Cigarette Sales, Inclines Toward RRPs
by Zacks Equity Research
Altria (MO) is undertaking efforts to expand in the RRPs space amid receding cigarette shipping volumes.
Altria (MO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $57.30 in the latest trading session, marking a +0.97% move from the prior day.
IMBBY vs. MO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IMBBY vs. MO: Which Stock Is the Better Value Option?